Current chemotherapeutic strategies against bladder cancer
作者： Yozo Mitsui , Hiroaki Yasumoto , Naoko Arichi , Satoshi Honda , Hiroaki Shiina
DOI: 10.1007/S11255-011-0009-8
关键词: Combination chemotherapy 、 Oncology 、 Gemcitabine 、 Regimen 、 Doxorubicin 、 Chemotherapy 、 Cisplatin 、 Bladder cancer 、 Medicine 、 Vinblastine 、 Internal medicine 、 Urology 、 Nephrology
摘要: Urothelial cancer is a chemotherapy-sensitive malignancy, with the regimen of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) until recently considered to be first choice for chemotherapy. Poor survival substantial toxicity associated M-VAC have led investigations into alternative chemotherapy strategies, combination gemcitabine (GC) may promising. In addition, taxanes along and/or platinum-based agents also provide clinical benefits as second-line following or GC therapy. near future, results trials using molecular target therapies bring improved outcomes patients bladder cancer.
springer.com
sci-hub.se 参考文章(69)
B. J. M. Braakhuis, G. J. Peters, C. M. Kuiper, G. Veerman, V. W. T. Ruiz Van Haperen, A. M. Bergman, Interaction between cisplatin and gemcitabine in vitro and in vivo. Seminars in Oncology. ,vol. 22, pp. 72- 79 ,(1995)
M. Igawa, T. Ohkuchi, T. UekI, M. Ueda, K. Okada, T. Usui, Usefulness and Limitations of Methotrexate, Vinblastine, Doxorubicin And Cisplatin for the Treatment of Advanced Urothelial Cancer Journal of Urology. ,vol. 144, pp. 662- 665 ,(1990) , 10.1016/S0022-5347(17)39548-4
Urs E. Studer, Marisa Bacchi, Cédric Biedermann, Peter Jaeger, Rainer Kraft, Luca Mazzucchelli, Regula Markwalder, Edgar Senn, Roland W. Sonntag, Adjuvant Cisplatin Chemotherapy Following Cystectomy for Bladder Cancer: Results of a Prospective Randomized Trial Journal of Urology. ,vol. 152, pp. 81- 84 ,(1994) , 10.1016/S0022-5347(17)32822-7
Cora N. Sternberg, Alan Yagoda, Howard I. Scher, Robin C. Watson, Harry W. Herr, Michael J. Morse, Pramod C. Sogani, E. Darracott Vaughan, Neil Bander, Lora R. Weiselberg, Nancy Geller, Phyllis S. Hollander, Roberta Lipperman, William R. Fair, Willet F. Whitmore, M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. The Journal of Urology. ,vol. 139, pp. 461- 469 ,(1988) , 10.1016/S0022-5347(17)42494-3
Robert Dreicer, Hailun Li, Mark Stein, Robert DiPaola, Michael Eleff, Bruce J. Roth, George Wilding, Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer. ,vol. 115, pp. 4090- 4095 ,(2009) , 10.1002/CNCR.24467
Robert Dreicer, Judith Manola, Bruce J. Roth, William A. See, Steven Kuross, Martin J. Edelman, Gary R. Hudes, George Wilding, Phase III Trial of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin versus Carboplatin and Paclitaxel in Patients with Advanced Carcinoma of the Urothelium: A Trial of the Eastern Cooperative Oncology Group Cancer. ,vol. 100, pp. 1639- 1645 ,(2004) , 10.1002/CNCR.20123
R S Witte, P Elson, B Bono, R Knop, R R Richardson, R Dreicer, P J Loehrer, Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. Journal of Clinical Oncology. ,vol. 15, pp. 589- 593 ,(1997) , 10.1200/JCO.1997.15.2.589
Enrico Crucitta, Nicola Silvestris, P Comella, D Muci, Vito Lorusso, G Pezzella, S Mancarella, G. Rosati, A Mangiameli, A Sobrero, Gebbia, M. De Lena, S Palmeri, L. Manzione, Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium. Oncology Reports. ,vol. 13, pp. 283- 287 ,(2005) , 10.3892/OR.13.2.283
J A McCaffrey, S Hilton, M Mazumdar, S Sadan, W K Kelly, H I Scher, D F Bajorin, Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. Journal of Clinical Oncology. ,vol. 15, pp. 1853- 1857 ,(1997) , 10.1200/JCO.1997.15.5.1853
M J Moore, I F Tannock, D S Ernst, S Huan, N Murray, Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. Journal of Clinical Oncology. ,vol. 15, pp. 3441- 3445 ,(1997) , 10.1200/JCO.1997.15.12.3441